BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Londei M, Quaratino S, Maiuri L. Celiac disease: a model autoimmune disease with gene therapy applications. Gene Ther 2003;10:835-43. [PMID: 12732869 DOI: 10.1038/sj.gt.3302041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Londei M, Ciacci C, Ricciardelli I, Vacca L, Quaratino S, Maiuri L. Gliadin as a stimulator of innate responses in celiac disease. Molecular Immunology 2005;42:913-8. [DOI: 10.1016/j.molimm.2004.12.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
2 Kwon JH, Farrell RJ. Recent Advances in the Understanding of Celiac Disease: Therapeutic Implications for the Management of Pediatric Patients. Pediatric Drugs 2006;8:375-88. [DOI: 10.2165/00148581-200608060-00005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Polyak S, Mah C, Porvasnik S, Herlihy JD, Campbell-Thompson M, Byrne BJ, Valentine JF. Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5. Dig Dis Sci 2008;53:1261-70. [PMID: 17934813 DOI: 10.1007/s10620-007-9991-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
4 van der Marel S, Comijn EM, Verspaget HW, van Deventer S, van den Brink GR, Petry H, Hommes DW, Ferreira V. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy. Inflamm Bowel Dis. 2011;17:2436-2442. [PMID: 21370319 DOI: 10.1002/ibd.21673] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
5 Frossi B, De Carli M, Calabrò A. Coeliac Disease and Mast Cells. Int J Mol Sci 2019;20:E3400. [PMID: 31373285 DOI: 10.3390/ijms20143400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
6 Szebeni B, Veres G, Dezsofi A, Rusai K, Vannay A, Bokodi G, Vásárhelyi B, Korponay-Szabó IR, Tulassay T, Arató A. Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease. J Pediatr Gastroenterol Nutr. 2007;45:187-193. [PMID: 17667714 DOI: 10.1097/mpg.0b013e318064514a] [Cited by in Crossref: 61] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
7 Bethune MT, Khosla C. Oral enzyme therapy for celiac sprue. Methods Enzymol 2012;502:241-71. [PMID: 22208988 DOI: 10.1016/B978-0-12-416039-2.00013-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
8 Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Rispo A, Griffin M, Issekutz T, Quaratino S, Londei M. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 2005;129:1400-13. [PMID: 16285941 DOI: 10.1053/j.gastro.2005.07.054] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 5.1] [Reference Citation Analysis]